Wave Life Sciences：FDA会议定于WVE-006加速批准路径

FDA批准了Wave的会议请求，以讨论WVE-006在AATD中的加速批准路径。会议定于2026年夏末举行，此前RestorAATion-2数据积极，显示野生型AAT蛋白恢复及动态反应。

关键事实

申报时间: 2026年7月30日 11:38
事件: 顾问委员会已排期
方向: 积极
公司: WVEWave Life Sciences
资产: WVE-006
来源: SEC 8-K
可信度: 有来源

来源摘录

EX-99.1 2 d177737dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007’s potential in MASH, type 2 diabetes, and other cardiometabolic diseases Phase 2 combination with incretin and post-incretin maintenance trials of WVE-007 on track to initiate in 2H 2026 FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing); data from RestorAATion-2 trial support differentiated therapeutic approach for both lung and liver manifestations of AATD CTA submissi

SEC 8-K